GlassScriptPhysician profile
Raymond I Press
NPI 1215991302
$16,545.17
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,564 · 2020: $3,455 · 2021: $3,629 · 2022: $3,753 · 2023: $125 · 2024: $18.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,232.72 | 2019-2024 | Otezla, Enbrel, Tavneos |
| Horizon Therapeutics Plc | $2,093.04 | 2019-2022 | |
| Abbvie INC. | $1,311.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,299.26 | 2019-2022 | |
| Radius Health, INC. | $1,254.39 | 2019-2021 | |
| Ucb, INC. | $1,087.88 | 2019-2022 | |
| Janssen Biotech, INC. | $826.04 | 2019-2022 | |
| Celgene Corporation | $697.62 | 2019 | |
| Mallinckrodt Hospital Products INC. | $682.97 | 2020-2022 | |
| Pfizer INC. | $595.38 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $498.44 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $463.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $376.96 | 2019-2022 | |
| Lilly USA, LLC | $318.14 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $300.37 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $276.32 | 2019-2021 | |
| Genentech USA, INC. | $244.93 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $232.74 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $230.51 | 2019-2022 | |
| Genzyme Corporation | $178.22 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $170.08 | 2021-2022 | |
| Zyla Life Sciences, INC. | $158.92 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $136.56 | 2019-2020 | |
| Eisai INC. | $125.47 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $124.69 | 2022 | |
| Medexus Pharma, INC. | $33.82 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $32.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.34 | 2021 | |
| Assertio Therapeutics, INC. | $27.21 | 2020 | |
| Hikma Pharmaceuticals USA | $21.22 | 2019 | |
| Kaleo, INC. | $13.76 | 2021 | |
| Bioventus LLC | $13.23 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Press listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.